Abiopharma

🔍 van Gunsteren Job Leonard (Executive)

Company: BALCHEM CORP (BCPC)

Report Date: 2026-02-11

Detailed Transactions and Holdings:

• Acquired 430 shares of Common Stock (Direct)
  Date: 2026-02-11 | Code: A | equity_swap_involved: 0 | shares_owned_after: 9,618.00 | transaction_form_type: 4 | Footnotes: F1
• Acquired 1,345 shares of Common Stock (Direct)
  Date: 2026-02-11 | Code: A | equity_swap_involved: 0 | shares_owned_after: 10,963.00 | transaction_form_type: 4 | Footnotes: F2
• Sold 756 shares of Common Stock at $178.68 per share (Direct)
  Date: 2026-02-11 | Code: F | equity_swap_involved: 0 | shares_owned_after: 10,207.00 | transaction_form_type: 4 | Footnotes: F3
• Sold 58 shares of Common Stock at $177.49 per share (Direct)
  Date: 2026-02-12 | Code: F | equity_swap_involved: 0 | shares_owned_after: 10,149.00 | transaction_form_type: 4 | Footnotes: F4
• Acquired 1,600 shares of Stock Option at $178.68 per share (Derivative)
  Date: 2026-02-11 | Code: A | Expires: 2036-02-11 | equity_swap_involved: 0 | shares_owned_after: 1,600.00 | transaction_form_type: 4 | Footnotes: F5

Footnotes:

• F1: Ownership of restricted stock vests in Reporting Person over a 3-year period (25% on the first anniversary of the grant date, 25% on the second anniversary of the grant date, and 50% on the third anniversary of the grant date), subject to restrictions on transfer in accordance with the provisions of a Restricted Stock Grant Agreement between the Issuer and the Reporting Person.
• F2: Represents the vesting of performance stock units (includes 22 dividend equivalent shares) for the 2023-2025 performance period.
• F3: 756 of the 1,345 performance stock units that vested on February 11, 2026 were withheld to cover tax requirement due upon vesting.
• F4: Reflects shares that were withheld to cover withholding taxes due upon vesting of restricted shares (granted on 2/12/2025).
• F5: Options vest 20% Year 1, 40% Year 2, and 40% Year 3.